Dana-Farber Cancer Institute

Lymphoma Clinical Trials and Research

    In this section

    New Patient Appointments

    877-442-3324
    MAKE APPOINTMENT ONLINE

    New Patient Appointments

    877-442-3324
    REQUEST AN APPOINTMENT

    Clinical Trials Questions?

    877-338-7425

    The overarching mission of our Lymphoma Program is to develop more effective and safer treatments for patients with lymphoma. We aim to improve outcomes, reduce side effects, and, over time, move closer to curative therapies for all patients with lymphoma and chronic lymphocytic leukemia (CLL). Guided by what we learn from caring for patients and discoveries from our mechanistic laboratory research, our team leads a wide range of cutting-edge clinical trials that provide access to promising new therapies before they are widely available. 

    We offer clinical trials for many different subtypes of lymphoma and CLL, and for patients with both newly diagnosed and relapsed or refractory disease. We leverage different types of novel therapies including targeted small molecules, CAR T cells, and bispecific antibodies. Laboratory, computational, and data scientists work to identify measurable features of patients and their lymphomas that explain and, in some cases, predict clinical outcomes to guide future efforts to match patients with the treatments from which they will derive maximum benefit. 

    Our entire team collaborates to conceive and evaluate biologically informed treatment strategies that bring us closer to well-tolerated cures for as many patients as possible.

    On This Page:

    Murakami Lab Advances Safer, More Effective Treatments for Lymphoma

    Mark Murakami, MD, provides an overview of the Murakami Lab, which is dedicated to advancing more durable treatments for patients with lymphoma. The research team at the Murakami Lab studies patient blood and biopsy samples to understand why some lymphomas respond better to treatment than others and to identify new targets for therapy. Using patient-derived lymphoma models, the team also tests promising treatment strategies that may help shape future clinical trials.

    Chronic Lymphocytic Leukemia (CLL) Clinical Trials

    Watchful Waiting

    Trial 22-597: Randomized, phase 3 Study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with CLL: EVOLVE CLL study
    Principal Investigator: Inhye Ahn, MD

    Consolidation

    Trial 25-277: A pilot study evaluating mosunetuzumab for clearance of detectable minimal residual disease in chronic lymphocytic leukemia
    Principal Investigator: Inhye Ahn, MD

    Relapsed/Refractory

    Trial 25-886: A phase 2 pilot study of mirdametinib in relapsed refractory chronic lymphocytic leukemia   
    Principal Investigator: Jennifer Brown, MD, PhD

    Trial 25-807:  The MAVRiC Study: A phase 2 study of disease risk mutation-guided finite duration acalabrutinib plus venetoclax for relapse in CLL/SLL after first-line finite covalent BTKi plus BCL2i combination, with or without obinutuzumab
    Principal Investigator: Matthew Davids, MD, MMSc

    Trial 24-449: Randomized trial of venetoclax + rituximab/obin w/ or w/o roginolisib, novel PI3K-delta inhibitor
    Principal Investigator: Jennifer Brown, MD, PhD

    Trial 24-444: A phase 1/2 open-label multi-centre master protocol to evaluate the safety and efficacy of AZD0486 monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies
    Principal Investigator: Matthew Davids, MD, MMSc

    Trial 23-126: A phase 1/2, open-label, dose-escalation and expansion study of the bruton tyrosine kinase-targeted protein-degrader BGB-16673 in patients with B-cell malignancies
    Principal Investigator: Inhye Ahn, MD

    Trial 21-712: A multicenter, open-label, phase 2 study to evaluate the efficacy and safety of venetoclax- obinutuzumab retreatment in patients with recurring chronic lymphocytic leukemia
    Principal Investigator: Matthew Davids, MD, MMSc

    Trial 21-414: An open label phase 1a/b dose escalation followed by dose expansion safety and tolerability trial of CAP-100, A Humanized C-C-Chemokine receptor 7 antibody, administered as monotherapy in subjects with R/R chronic lymphocytic leukemia
    Principal Investigator: Jennifer Brown, MD, PhD

    Richter's Transformation

    Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
    Principal Investigator: David Qualls, MD

    Trial 23-429: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin, pirtobrutinib, or atezolizumab in Richter's Transformation
    Principal Investigator: Christine Ryan, MD

    Learn more about ongoing research being conducted at our Center for Chronic Lymphocytic Leukemia.

    Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

    Newly-Diagnosed

    Trial 25-725: A randomized, open-label, multicenter, phase 2 study evaluating the efficacy and safety of zilovertamab vedotin (MK-2140) plus R-CHP Versus polatuzumab vedotin plus R-CHP in treatment-naïve participants with GCB subtype of diffuse large B-cell lymphoma (DLBCL)
    Principal Investigator: Jennifer Crombie, MD

    Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
    Principal Investigator: Caron Jacobson, MD, MMSc

    For transformed follicular lymphoma, marginal zone lymphoma, or other transformed indolent lymphomas

    Trial 22-606: A phase 2 study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma
    Principal Investigator: Jennifer Crombie, MD

    Relapsed/Refractory

    Trial 26-048: A first-in-human, multicenter phase 1a/1b study to investigate safety, tolerability, and preliminary efficacy of LY4584180 in adult participants with previously treated hematologic malignancies
    Principal Investigator: David Qualls, MD

    Trial 24-253: A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Principal Investigator: David Qualls, MD

    Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
    Principal Investigator: David Qualls, MD

    Trial 22-451: A phase 2/3 multicenter, open-label, randomized, active-control study of zilovertamab vedotin (MK-2140) in combination with standard of care in participants with   relapsed or refractory diffuse large B-cell lymphoma. (waveLINE-003)
    Principal Investigator: David Qualls, MD

    Follicular Lymphoma Clinical Trials

    Newly-Diagnosed

    Trial 22-702: A phase 2 study of epcoritamab and rituximab for first-line treatment of follicular lymphoma
    Principal Investigator: Reid Merryman, MD

    Relapsed/Refractory

    Trial 24-006: A phase 1/2, multi-center, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458, alone and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin lymphomas (R/R NHL)
    Principal Investigator: David Qualls, MD

    Learn more about ongoing research being conducted at our Follicular Lymphoma Center.

    Histiocyte Disorders Clinical Trials

    Trial 22-548: A phase 2 study to assess the safety and efficacy of cobimetinib in refractory Langerhans cell histiocytosis, LCH-associated neurodegenerative disease, and other histiocytic disorders
    Principal Investigator: Eric Jacobsen, MD

    Hodgkin Lymphoma Clinical Trials

    Newly-Diagnosed

    Trial 23-553: A randomized phase 3 interim response adapted trial comparing standard therapy with immunooncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma
    Principal Investigator: Ann S. LaCasce, MD, MMSc

    Relapsed/Refractory

    Trial 22-121: A phase 2 study of brentuximab vedotin plus nivolumab without stem cell consolidation in patients with relapsed/refractory classical Hodgkin lymphoma
    Principal Investigator: Reid Merryman, MD

    Mantle Cell Lymphoma (MCL) Clinical Trials

    Newly-Diagnosed

    Trial 24-654: A randomized phase 2 study of bendamustine, rituximab, cytarabine (AraC) induction with zanubrutinib (BRAZAN) followed by zanubrutinib/rituximab +/- sonrotoclax maintenance in treatment-naïve mantle cell lymphoma
    Principal Investigator: Christine Ryan, MD

    Trial 21-040: a phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma
    Principal Investigator: Austin Kim, MD

    Learn more about ongoing research being conducted at our Mantle Cell Lymphoma Center.

    Relapsed/Refractory

    Trial 26-048: A first-in-human, multicenter phase 1a/1b study to investigate safety, tolerability, and preliminary efficacy of LY4584180 in adult participants with previously treated hematologic malignancies
    Principal Investigator: David Qualls, MD

    Trial 25-264: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma 
    Principal Investigator: Christine Ryan, MD

    Trial 24-444: A phase 1/2 open-label multi-centre master protocol to evaluate the safety and efficacy of AZD0486 monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies
    Principal Investigator: Matthew Davids, MD, MMSc  

    Trial 21-124: A multi-center single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
    Principal Investigator: Caron Jacobson, MD, MMSc

    Marginal Zone Lymphoma (MZL) Clinical Trials

    Relapsed/Refractory

    Trial 26-048: A first-in-human, multicenter phase 1a/1b study to investigate safety, tolerability, and preliminary efficacy of LY4584180 in adult participants with previously treated hematologic malignancies
    Principal Investigator: David Qualls, MD

    Trial 24-393: A phase 2 study of epcoritamab, zanubrutinib, and rituximab (EZR) for treatment of relapsed or refractory follicular lymphoma or marginal zone lymphoma
    Principal Investigator: Reid Merryman, MD

    Learn more about ongoing research being conducted at our Marginal Zone Lymphoma Center.

    Primary Mediastinal Large B Cell Lymphoma (PMBCL) Clinical Trials

    Trial 23-179: A phase 2 trial of pembrolizumab in combination with chimeric antigen receptor therapy in patients with relapsed/refractory primary mediastinal B-cell lymphoma
    Principal Investigator: Jennifer Crombie, MD

    T-Cell Lymphoma Clinical Trials

    Relapsed/Refractory

    Trial 24-459: An open-label, multi-center, non-randomized phase 1 dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell lymphoma
    Principal Investigator: Eric Jacobsen, MD

    Trial 24-165: A phase 2 study evaluating the efficacy of ruxolitinib in patients with T-cell large granular lymphocytic leukemia (T-LGLL)
    Principal Investigator: Eric Jacobsen, MD